Analysts’ Recent Ratings Changes for Nuvation Bio (NUVB)

Posted by on Aug 6th, 2026

A number of firms have modified their ratings and price targets on shares of Nuvation Bio (NYSE: NUVB) recently:

  • 7/27/2026 – Nuvation Bio had its price target raised by HC Wainwright from $17.00 to $21.00. They now have a “buy” rating on the stock.
  • 7/23/2026 – Nuvation Bio had its “outperform” rating reaffirmed by Wedbush. They now have a $11.00 price target on the stock.
  • 7/22/2026 – Nuvation Bio had its “outperform” rating reaffirmed by Royal Bank Of Canada.
  • 7/17/2026 – Nuvation Bio had its “sell (d-)” rating reaffirmed by Weiss Ratings.
  • 7/7/2026 – Nuvation Bio had its price target lowered by Royal Bank Of Canada from $20.00 to $19.00. They now have an “outperform” rating on the stock.
  • 7/7/2026 – Nuvation Bio had its price target raised by Truist Financial Corporation from $12.00 to $13.00. They now have a “buy” rating on the stock.
  • 7/6/2026 – Nuvation Bio was upgraded by Zacks Research from “strong sell” to “hold”.
  • 6/10/2026 – Nuvation Bio had its “market outperform” rating reaffirmed by Citigroup Inc..

Insider Activity

In other Nuvation Bio news, CFO Philippe Sauvage sold 47,668 shares of the business’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $6.01, for a total transaction of $286,484.68. Following the sale, the chief financial officer directly owned 12,673 shares of the company’s stock, valued at $76,164.73. The trade was a 79.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert Mashal bought 25,000 shares of Nuvation Bio stock in a transaction dated Tuesday, June 9th. The stock was acquired at an average price of $4.73 per share, with a total value of $118,250.00. Following the acquisition, the director directly owned 225,000 shares of the company’s stock, valued at approximately $1,064,250. This represents a 12.50% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders sold 235,668 shares of company stock worth $1,419,495. Company insiders own 30.11% of the company’s stock.

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.

See Also

Receive News & Ratings for Nuvation Bio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvation Bio Inc and related companies with MarketBeat.com's FREE daily email newsletter.